DaVita Inc. (NYSE:DVA) Short Interest Update

DaVita Inc. (NYSE:DVA) was the recipient of a significant drop in short interest during the month of January. As of January 15th, there was short interest totaling 6,943,051 shares, a drop of 14.2% from the December 31st total of 8,092,541 shares. Currently, 10.0% of the shares of the company are short sold. Based on an average daily trading volume, of 975,529 shares, the days-to-cover ratio is currently 7.1 days. Based on an average daily trading volume, of 975,529 shares, the days-to-cover ratio is currently 7.1 days. Currently, 10.0% of the shares of the company are short sold.

DaVita Price Performance

Shares of NYSE:DVA opened at $134.55 on Wednesday. The firm has a market capitalization of $9.50 billion, a price-to-earnings ratio of 13.58, a price-to-earnings-growth ratio of 0.68 and a beta of 0.99. The business’s 50 day simple moving average is $113.69 and its 200-day simple moving average is $124.82. DaVita has a 12 month low of $101.00 and a 12 month high of $178.47.

DaVita (NYSE:DVA) last issued its quarterly earnings data on Monday, February 2nd. The company reported $3.40 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.24 by $0.16. The firm had revenue of $3.62 billion during the quarter, compared to analysts’ expectations of $3.51 billion. DaVita had a negative return on equity of 586.45% and a net margin of 5.47%.DaVita’s revenue was up 9.9% on a year-over-year basis. During the same period in the previous year, the firm posted $2.24 earnings per share. DaVita has set its FY 2026 guidance at 13.600-15.00 EPS. On average, equities analysts anticipate that DaVita will post 10.76 earnings per share for the current year.

Analyst Ratings Changes

A number of analysts have weighed in on the company. UBS Group reaffirmed a “buy” rating on shares of DaVita in a research report on Monday, December 15th. Barclays increased their price target on DaVita from $143.00 to $158.00 and gave the stock an “equal weight” rating in a report on Tuesday. Zacks Research raised shares of DaVita from a “strong sell” rating to a “hold” rating in a research note on Friday, November 28th. Weiss Ratings restated a “hold (c)” rating on shares of DaVita in a research note on Monday, December 29th. Finally, Truist Financial dropped their price target on shares of DaVita from $140.00 to $128.00 and set a “hold” rating on the stock in a research note on Monday, January 5th. One investment analyst has rated the stock with a Buy rating, five have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Hold” and an average target price of $148.60.

Key Headlines Impacting DaVita

Here are the key news stories impacting DaVita this week:

• Positive Sentiment: Q4 beat — DaVita reported Q4 revenue of ~$3.62B and EPS above estimates, with margins expanding and full‑year adjusted EPS guidance raised materially above consensus, supporting a more bullish near‑term outlook. DaVita Stock Up Following Q4 Earnings & Revenue Beat, Margins Expand
• Positive Sentiment: Raised guidance — Management set FY‑2026 EPS guidance of $13.60–$15.00, above the Street, citing steady dialysis demand; that forward guidance was a key catalyst for the stock’s rally. DaVita forecasts 2026 profit above estimates on steady dialysis service demand
• Positive Sentiment: After‑hours flow and market reaction — Major outlets reported strong after‑hours buying and a sizable volume spike as investors repositioned around the beats and higher guidance. Stocks making the biggest moves after hours: Palantir, NXP Semiconductors, DaVita and more
• Neutral Sentiment: Management commentary & call — The company’s press release and earnings call described execution vs targets and patient demand trends; read the transcript/press release for management’s assumptions driving the guidance. DaVita Inc. 4th Quarter 2025 Results
• Neutral Sentiment: Analyst context — Recent price targets cluster near the low‑to‑mid $100s–$140s range (median ~$140), so the new guidance will force analysts to re‑rate estimates and targets in coming days. DaVita Inc. Releases Q4 2025 Earnings
• Negative Sentiment: Volatility & risk factors — Market commentary warns that reimbursement, regulatory changes and execution risks could keep the stock volatile despite the beat; investors should expect swings. DaVita: Some Success Is Possible, But Volatility Is Still Heavy
• Negative Sentiment: Some financials to watch — While EPS and revenue improved, third‑party summaries show cash & cash equivalents declined and liabilities rose year‑over‑year; monitor margin sustainability and cash/leveraging metrics. DaVita Inc. Releases Q4 2025 Earnings (financial highlights)

Hedge Funds Weigh In On DaVita

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in DVA. Elevation Wealth Partners LLC grew its position in shares of DaVita by 147.3% in the fourth quarter. Elevation Wealth Partners LLC now owns 277 shares of the company’s stock valued at $31,000 after purchasing an additional 165 shares during the last quarter. Hantz Financial Services Inc. lifted its stake in DaVita by 48.1% in the 2nd quarter. Hantz Financial Services Inc. now owns 231 shares of the company’s stock valued at $33,000 after buying an additional 75 shares in the last quarter. Mid American Wealth Advisory Group Inc. acquired a new stake in DaVita during the 2nd quarter valued at $36,000. Canada Pension Plan Investment Board purchased a new position in DaVita during the second quarter worth $43,000. Finally, iSAM Funds UK Ltd acquired a new position in shares of DaVita in the third quarter worth $46,000. Institutional investors and hedge funds own 90.12% of the company’s stock.

DaVita Company Profile

DaVita Inc (NYSE: DVA) is a leading provider of kidney care services, specializing in the management and operation of outpatient dialysis centers for patients with chronic kidney failure and end-stage renal disease. Headquartered in Denver, Colorado, the company offers a comprehensive suite of treatment modalities, including in-center hemodialysis, peritoneal dialysis, and home dialysis therapies. In addition to its core dialysis services, DaVita provides patient education, nutritional counseling, vascular access management and related laboratory services to support kidney health and overall patient well-being.

Since its formation in the mid-1990s through a clinical management services spin-off, DaVita has expanded both organically and through strategic partnerships and acquisitions.